# CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2016

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2016-08-02
- Accepted by EDGAR: Aug 2, 2016, 16:41 ET
- Period: 2016-06-30
- Accession: 0000064803-16-000090
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000006480316000090/cvs20160630-10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000006480316000090/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-04-01 to 2016-06-30 | $43.73bn | us-gaap:Revenues |
| Revenue | 6 months, 2016-01-01 to 2016-06-30 | $86.94bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-04-01 to 2016-06-30 | $36.71bn | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2016-01-01 to 2016-06-30 | $73.18bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-04-01 to 2016-06-30 | $7.01bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2016-01-01 to 2016-06-30 | $13.76bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2016-04-01 to 2016-06-30 | $2.35bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-01-01 to 2016-06-30 | $4.53bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-04-01 to 2016-06-30 | $284.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2016-01-01 to 2016-06-30 | $572.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-04-01 to 2016-06-30 | $604.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2016-01-01 to 2016-06-30 | $1.35bn | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2016-04-01 to 2016-06-30 | $0.86 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2016-01-01 to 2016-06-30 | $1.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-04-01 to 2016-06-30 | $0.86 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2016-01-01 to 2016-06-30 | $1.91 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-04-01 to 2016-06-30 | 1,075,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2016-01-01 to 2016-06-30 | 1,087,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2016-01-01 to 2016-06-30 | $4.02bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2016-01-01 to 2016-06-30 | $1.10bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2016-01-01 to 2016-06-30 | $929.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2016-01-01 to 2016-06-30 | $3.96bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-06-30 | $1.13bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-06-30 | $29.45bn | us-gaap:AssetsCurrent |
| Total assets | at 2016-06-30 | $92.75bn | us-gaap:Assets |
| Current liabilities | at 2016-06-30 | $26.57bn | us-gaap:LiabilitiesCurrent |
| Short-term borrowings | at 2016-06-30 | $745.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2016-06-30 | $34.76bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,063 characters.

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended June 30, 2016, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2014 Repurchase Program. See Note 3 - “Share Repurchase Programs” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10-Q for the three and six months ended June 30, 2016.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| April 2016 | 9,492,833 | $102.70 | 9,492,833 | $4,649,576,635 |
| May 2016 | 8,469,274 | $102.24 | 8,469,274 | $3,783,708,439 |
| June 2016 | 543,122 | $97.04 | 543,122 | $3,731,002,281 |
| Totals | 18,505,229 |  | 18,505,229 |  |

39

## Market risk

As filed, 335 characters.

As of June 30, 2016, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of June 30, 2016 its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.

## Controls and procedures

As filed, 1,440 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) as of June 30, 2016, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** On August 18, 2015, the Company completed its acquisition of Omnicare and on December 16, 2015, the Company completed its acquisition of the pharmacies and clinics of Target. As a result, the Company is in the process of integrating the applicable internal controls for each business into its internal control over financial reporting for the rest of the Company. Other than the foregoing, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended June 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Aug 2, 2016.
Source: SEC EDGAR, the filing index for accession 0000064803-16-000090. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
